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Abstract 
Purpose of review: SH2 domain-containing tyrosine phosphatase 2 (SHP2), 
encoded by PTPN11 plays an important role in regulating signaling from cell 
surface receptor tyrosine kinases during normal development as well as 
oncogenesis. Herein we review recently discovered roles of SHP2 in normal and 
aberrant hematopoiesis along with novel strategies to target it. 
Recent findings: Cell autonomous role of SHP2 in normal hematopoiesis and 
leukemogenesis has been recognized for long. The review will discuss the newly 
discovered role of SHP2 in lineage specific differentiation. Recently, a non-cell 
autonomous role of oncogenic SHP2 has been reported in which activated SHP2 
was shown to alter the bone marrow microenvironment resulting in 
transformation of donor derived normal hematopoietic cells and development of 
myeloid malignancy. From being considered as an ‘undruggable’ target, recent 
development of allosteric inhibitor has made it possible to specifically target 
SHP2 in receptor tyrosine kinase driven malignancies. 
Summary: SHP2 has emerged as an attractive target for therapeutic targeting in 
hematological malignancies for its cell autonomous and micro-environmental 
effects. However a better understanding of the role of SHP2 in different 
hematopoietic lineages and its crosstalk with signaling pathways activated by 
other genetic lesions is required before the promise is realized in the clinic.  
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SH2 domain-containing tyrosine phosphatase 2 (SHP2), a non-receptor 
tyrosine phosphatase is encoded by PTPN11 gene. It is a positive regulator of 
signaling downstream of several receptor tyrosine kinases such as cKIT and 
FLT3 [1,2]. Recruitment of SHP2 to an activated receptor releases the self-
inhibitory conformation and leads to catalytic activation of its phosphatase 
domain. In addition to its function as a phosphatase, SHP2 also serves as a 
docking protein to recruit other signaling intermediates through the two amino 
terminus SH2 domains. Since SHP2 is a positive regulator of cellular signaling 
leading to proliferation, differentiation and survival, its constitutive activation is 
associated with oncogenesis. 
 
SHP2 in Hematopoiesis 
Normal hematopoietic development and homeostasis is maintained by cell 
to cell interactions between cells of the hematopoietic system and their 
surroundings as well as through soluble mediators that include growth factors, 
cytokines and chemokines. Collectively these factors constitute a complex niche 
in which hematopoietic stem cells reside and wherein their function is governed 
by both cell autonomous genetic programs and niche properties [3]. Given that 
SHP2 plays a role in signaling through multiple tyrosine kinases in response to 
different cytokines, deregulation of SHP2 has broad consequences on 
hematopoiesis [4,5]. Mouse models with conditional deletion of Ptpn11, the gene 
encoding SHP2 have conclusively established an indispensable role for SHP2 in 
regulating normal hematopoietic stem cell (HSC) function [6,7]. According to 
general consensus, SHP2 is a positive regulator of hematopoiesis and loss of 
SHP2 or decrease in its catalytic activity is associated with reduced stem and 
progenitor cell numbers and function. Reciprocal transplantation experiments 
have shown that the defects in HSC function due to loss of SHP2 are primarily 
cell autonomous with no significant involvement of the bone marrow 
microenvironment [6,7]. Likewise, in human CD34+ cord blood cells, knockdown 
of SHP2 has been associated with decrease in cell growth and colony formation 
[8]. A similar reduction in colony formation were observed upon expression of 
SHP2 with a point mutation, resulting in loss of phosphatase function in human 
CD34+ cord blood cells [9]. Conversely, a gain of phosphatase function mutant of 
SHP2 promoted colony formation in this study. Interestingly, expression of a 
phosphatase domain truncated version of SHP2 with adaptor function intact 
functioned in a dominant negative manner [9]. These mouse models and human 
cord blood studies indicate that phosphatase function of SHP2 is integral to 
normal HSC function.  
At the molecular level, modulation in the expression of transcription factors 
such as GATA2, C/EBP and induction of p53 independent apoptosis in the stem 
and progenitor cell compartment have been implicated in deregulation of HSC 
number and function in response to loss of SHP2 [6,7]. Thus far, downregulation 
of the Ras- extracellular regulated kinase (ERK) signaling axis in the absence of 
SHP2 is considered as the major mediator of the above described molecular 
changes. Recently RUNX1, a master regulator of hematopoiesis, has been 
identified as a direct target of SHP2 phosphatase activity [10]. In the progenitor 
cells, RUNX1 is phosphorylated by Src family kinases (SFK) and removal of this 
phosphorylation by SHP2 is required during megakaryocyte differentiation [10]. 
The dephosphorylation of RUNX1 enabled its association with the transcription 
factors such as GATA1 and SWI/SNF chromatin remodeling complex for 
execution of megakaryocyte terminal differentiation program (Figure 1) [10]. 
Consistent with these findings, conditional deletion of Ptpn11 in megakaryocyte 
lineage cells is associated with suppression of thrombopoietin and integrin 
signaling, reduction in proplatelets and development of macrothrombocytopenia 
[11]. In addition to the megakaryocyte lineage, dephosphorylation of RUNX1 is 
also required for differentiation of T cells into CD8+ single positive cells [10]. 
Thymocytes with deletion of Ptpn11 show increase in RUNX1 phosphorylation 
and defects in the development of CD8+ cells [10]. Thus SHP2 plays an 
important role in regulating the transcriptional activity of RUNX1 during cellular 
differentiation through its phosphatase activity. Level of RUNX1 activity then 
determines the differentiation of the progenitor cells along either megakaryocyte 
or erythroid lineage. While RUNX1 promotes development of megakaryocytes, 
inhibits erythroid development through repression of KLF1 [12]. 
In line with this, expression of oncogenic Ptpn11 that is constitutively 
active blocks erythrocyte differentiation and maturation suggesting that 
downregulation of SHP2 activity is required for erythrocyte differentiation [13]. 
Interestingly, a similar block in erythrocyte differentiation was observed as a 
result of loss of SHP2 activity in the context of phosphatase and tensin homolog 
(PTEN) deficiency [14]. Contrasting results have been reported on the role of 
MAPK\ERK activation in erythropoiesis due to loss or gain of function of SHP2. In 
one study, MEK inhibitor U0126 inhibited the hyperproliferation of erythroblasts 
[13] while the other study using trametinib, another MEK inhibitor, phenocopied 
the loss of SHP2 mediated defect in erythropoiesis [14]. It is possible that these 
differences are due to off target effects of the different MEK inhibitors used in the 
two studies. Further studies are needed to clarify these contradictory 
observations and further clarify the role SHP2/ ERK axis in erythropoiesis. These 
cell lineage specific functions of SHP2 are going to be valuable while designing 
strategies to target SHP2 in hematological malignancies. 
 
SHP2 in Leukemogenesis 
SHP2 is the first phosphatase to be recognized as a bonafide oncogene. 
Constitutive activation of SHP2 in the hematopoietic stem and progenitor 
compartment due to point mutations in its N-terminus SH2 domain results in the 
development of cell autonomous leukemia in different cell lineages independent 
of the stage of differentiation [15]. In addition to the hematopoietic compartment, 
PTPN11 has been recognized as an oncogene in 41 different cancer types with 
Q510, A72, E76 and G503 identified as hotspots of mutation in a panel of 119 
tumors [16]. Interestingly, all these mutations have a positive impact on the 
phosphatase activity of SHP2 through either reducing regulatory N-SH2 domain 
(A72, E76) interaction with the catalytic domain or alter the active site (G503, 
Q510) [17,18]. Mutations in PTPN11 that lead to alterations in the catalytic 
activity of SHP2 have been implicated in pathogenesis of Noonan syndrome 
(NS), Leopard syndrome (LS) and juvenile myelomonocytic leukemia (JMML) 
[4,5]. PTPN11 is also frequently mutated in secondary acute myeloid leukemia 
(AML) [19], relapsed pediatric AML [20] and acute lymphoblastic leukemia (ALL) 
[21]. The frequency of PTPN11 mutations in AML is higher in patients older than 
60yrs [22] and also has prognostic significance. Secondary AML patients 
carrying mutations in PTPN11 show rapid disease progression and reduced 
overall survival [19]. In AML, PTPN11G503A mutation has been reported to co-
occur with mixed lineage leukemia (MLL) translocation, MLL-AF10. In a mouse 
model co-expression of MLL-AF10 and PTPN11G503A resulted in accelerated 
disease development as compared to MLL-AF10 alone [23]. Increase in leukemia 
stem cell frequency along with rapid AML development is also seen when 
Ptpn11E76K is co-expressed with MLL-AF9 fusion oncogene [24]. In presence of 
mutant PTPN11, the leukemic cells show increase in the transcription of colony 
stimulating factor 1 (Csf1) and secretion of macrophage colony stimulating factor 
(M-CSF) resulting in enhanced differentiation of HSCs into myeloid lineage cells 
[23]. Although co-expression of MLL-AF9 with constitutively active SHP2 does 
not alter the expression of Meis1 or HoxA9 [24], it can reverse cytokine induced 
tyrosine phosphorylation of HoxA9 and HoxA10 leading to sustained expression 
of CDX4, a homeodomain transcription factor (Figure 2) [25]. During normal 
myelopoiesis CDX4 is downregulated as HSCs differentiate into myeloid cells. 
Thus its sustained high expression would inhibit differentiation and contribute to 
more stem cell like phenotype of leukemic cells. AML cells co-expressing mutant 
Ptpn11 with MLL fusion oncogenes are also more resistant to Mcl-1 inhibitor and 
daunorubicin [23,24]. These studies provide insights into how co-existence of 
PTPN11 mutations can alter disease progression and drug resistance.  
Recent studies have shed novel light on our understanding of the non-cell 
autonomous role of constitutively active SHP2 in leukemogenesis. Bone marrow 
transplant recipients are known to develop donor cell derived secondary 
leukemia. One of the contributing factor resulting in this observation likely relates 
to the oncogenic signaling initiated by the microenvironment [3,26]. The 
microenvironment induced leukemogenic effects could be a result of the 
presence of genetic aberrations in the microenvironmental cells or modulation of 
the niche by leukemic cells [3,26]. Dong et al [27] have shown that expression of 
Noonan syndrome associated leukemogenic Ptpn11 mutations in mesenchymal 
stem and osteoprogenitor cells can modulate chemokine and cytokine secretion 
resulting in a favorable environment for recruitment of monocytes to the HSC 
niche (Figure 3). The inflammatory nature of such modified stem cell niche 
promotes myeloid hyperproliferation and development of donor derived 
myeloproliferative neoplasm (MPN). Using conditional activation of leukemogenic 
Ptpn11, authors demonstrated that donor cell derived MPN was observed only 
when the mutant Ptpn11 was expressed in mesenchymal stem and bone 
progenitor cells [27]. Expression of mutant Ptpn11 in more differentiated cells 
such as osteoblasts or endothelial cells did not induce donor derived MPN. In 
addition, antagonist of CCL3 receptor mitigated development of donor derived 
MPN confirming the pivotal role of modulation of secreted factors in driving 
cellular transformation. These studies underline the importance of targeting the 
alterations in the microenvironment for successful therapy of diseases involving 
germline PTPN11 mutations.   
 
Targeting SHP2 in Hematological Malignancy 
Targeting the aberrant signaling through tyrosine kinase inhibitors (TKI) 
led to initial success but subsequent acquisition of resistance to TKI due to 
additional mutations has been a major challenge in the long-term management of 
these malignancies [28,29]. Therefore, efforts have shifted to target further 
downstream mediators of the oncogenic signals [29]. While constitutively active 
SHP2 leads to the development of hematological malignancies such as JMML, 
wild type SHP2 is required by oncogenic tyrosine kinases for cellular 
transformation [30-32]. Thus, SHP2 has emerged as a therapeutic target not only 
for diseases involving PTPN11 mutations but also in malignancies driven by 
receptor tyrosine kinases such as AML, MPN. However, traditionally 
phosphatases have been considered as undruggable in part due to the inability 
to efficiently and selectively target their catalytic site with cell permeable small 
molecule inhibitors [33]. Protein phosphatases have highly conserved residues 
around catalytic sites, and therefore attaining selectivity has been a formidable 
challenge. Over the course of last several years, efforts have been made to 
develop inhibitors of SHP2 for clinical use based on their activity in vitro and in 
vivo [34]. However, despite promising pre-clinical results, little progress has been 
made in translating these findings into clinic. Thus far, only one SHP2 inhibitor, 
Sodium Stibogluconate (SB), also known as Pentostam has entered clinical 
trials. It is one of the first known compounds to irreversibly inhibit SHP2 along 
with related phosphatases such as SHP1 and PTP1B in hematopoietic cells [35]. 
Phase I/II clinical trials were conducted with co-administration of SB with IFN- 
α2B in advanced cancers and melanoma with or without chemotherapy 
(NCT00629200 and NCT00498979). Though the drug combination was well 
tolerated in patients with decrease in target phosphoproteins in peripheral blood; 
but no objective disease regression was observed in any of the patients [36].  
Development of allosteric inhibitors has been a major step in overcoming 
non-specificity in targeting phosphatases. Since allosteric inhibitors do not bind to 
the catalytic site, they can be targeted to the non-conserved domains of the 
protein to alter the active site structure and function. The pharmaceutical 
company, Novartis has recently been successful in identifying a small molecule 
allosteric inhibitor of SHP2 from a library of compounds [37,38]. SHP099, 
obtained after a series of optimization steps, is a potent, orally bioavailable 
allosteric inhibitor of SHP2 that selectively inhibits the proliferation of receptor 
tyrosine kinase driven cancer cell lines in vitro without impacting BRAF or KRAS 
driven cancer cells [38]. SHP099 was also shown to be effective in vivo models 
of tumor xenograft including in AML model. Inhibition of growth of cancer cells 
correlated with the ability of SHP099 to downregulate ERK signaling pathway 
with no significant impact on the phosphatidylinositol-3-kinase (PI3K)/AKT 
pathway. Interestingly, SHP099 was as effective as the FDA approved EGFR 
tyrosine kinase inhibitor, Erlotinib in inhibiting activation of ERK and tumor growth 
in xenograft models [38]. Additionally, negligible activity against a broad panel of 
phosphatases, kinases and other potential off target effectors strongly suggest 
that SHP099 is highly specific for SHP2 [38]. However, it still remains to be seen 
whether allosteric inhibition will be as successful against leukemogenic SHP2 
wherein the self-inhibitory state is perturbed. In addition to the chemically 
synthesized inhibitors, recently Fumosorinone (Fumos) has been isolated from 
entomogenous fungi and characterized as an effective inhibitor of SHP2 [39]. 
Similar to SHP099, Fumos showed significant inhibition of the RAS/ERK pathway 
downstream of EGFR but was ineffective in the presence of oncogenic RAS or 
phorbol myristate acetate (PMA) [39]. With the development and availability of 
such specific and potent inhibitors of SHP2, the likelihood of moving these drugs 
in clinic seems imminent.  
Some unintended consequences in non-myeloid lineage cells due to 
targeting SHP2 for myeloid malignancies have also been described. Zhu and 
colleagues [14] have shown that inhibition of SHP2 using either a genetic or a 
chemical approach though successful in ameliorating myeloid cell 
hyperproliferation induced by loss of PTEN, appeared to have a negative impact 
on red blood cells (RBC), resulting in anemia and shortened overall life span. In 
these studies, a similar effect was observed when mice were treated with MEK 
inhibitor, trametinib highlighting the differential role of the MEK/ERK pathway in 
myeloid versus erythroid lineages. While proliferation was suppressed in myeloid 
lineage cells; in the erythroid progenitor cells differentiation into mature RBCs 
was blocked [14]. Interestingly, treatment with antioxidants partially rescued 
these mice from development of anemia by extending the lifespan of erythrocytes 
but had no significant impact on differentiation of erythroblasts [14]. Though the 
molecular mechanisms for the differential impact of inhibition of Shp2/MEK/ERK 
on myeloid versus erythroid lineage cells are not clear, AKT 
hyperphosphorylation may be one of the factors. AKT phosphorylation is 
abrogated in myeloid cells due to loss of SHP2 in the context of PTEN deficiency; 
however it remained elevated in TER119+ erythroblasts [14]. Therefore, it may be 
essential to investigate the impact of SHP2 inhibition in cells that are not 
intended to be targeted especially in the context of additional genetic aberrations 
present. These deleterious effects on erythroid lineage were not observed by 
loss of SHP2 alone but only in the presence of concurrent loss of PTEN and 
SHP2.  To this end, PI3K/AKT inhibitors are being actively pursued in pre-clinical 
and clinical trials in various hematological malignancies [40]. Association of 
GAB2 with mutant SHP2 can also activate the PI3K/AKT/mTOR pathway and 
inhibition of mTOR by rapamycin ameliorates myeloid cell expansion [41]. Similar 
results have been shown with inactivation of the PI3K catalytic unit p110δ or the 
regulatory unit coded by Pik3r1 in oncogenic Ptpn11 dependent model of JMML 
[42,43]. In these studies, hypersensitivity to GM-CSF is lost in the absence of 
activation of the PI3K/AKT pathway. Consistent with these observations, a 
combination of SHP2 inhibitor IIB08 and PI3K inhibitor, LY294002 shows 
synergism in inhibiting cell proliferation and prolonging survival in receptor 
tyrosine kinase driven lung carcinoma and MPN models [30,44]. Similar benefits 
of combined targeting have been observed in vitro with SHP2 inhibitor, IIB08 and 
SYK inhibitor R406 through their effects on STAT5 pathway in FLT3-ITD AML 
cells [45]. With the availability of newer more specific, potent and well tolerated 
SHP2 inhibitor such as SHP009, it should be possible to further explore the 
combinations that give best effect with least toxicity and off target effects in 
hematological malignancies.  
 
In conclusion, SHP2 is a crucial node for integration of signals from 
different cell surface receptors with all the major cellular signaling pathways 
within the cells. Therefore, while aberrant activation of SHP2 triggers activation of 
signaling pathways leading to the development of hematological malignancies; it 
also provides a vulnerable therapeutic target. However, given its ubiquitous 
expression and functional role in different tissues and organs further studies are 
needed before SHP2 targeted therapeutics enter the clinic.   
 
Key points 
 PTPN11 mutations are frequently present in hematological malignancies 
and carry prognostic significance. 
 Constitutive activation of SHP2 has both cell autonomous and non-cell 
autonomous role in pathogenesis of myeloid hyperproliferation. 
 Highly selective small molecule allosteric SHP2 inhibitor, SHP099 is 
effective in suppressing growth of receptor tyrosine kinase driven tumor 
cells both in vitro and in vivo. 
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Legends to figures 
 
Figure 1: SHP2 regulates RUNX1 interaction with GATA1 and SWI/SNF 
chromatin remodeling complex during megakaryocyte and T cell differentiation. 
The auto-inhibitory domain of RUNX1 is phosphorylated by SFK in progenitor 
cells and is dephosphorylated by SHP2. 
 
Figure 2:  Constitutive activation of SHP2 suppresses the phosphorylation of 
HoxA9 in response to differentiation inducing cytokines during myelopoiesis. This 
leads to increased expression of CDX4 transcription factor and block in 
differentiation. 
 
Figure 3: Expression of mutant Ptpn11 in MSC and osteo-progenitor cells leads 
to donor cell derived myeloproliferation. Mutant Ptpn11 expressing MSC and 
osteo-progenitor cells have increased secretion of chemokine, CCL3 which 
recruits inflammatory IL-
changes in the niche contribute to loss of HSC quiescence and increased 
myeloid lineage commitment. 
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